Anti-CD47 antibodies and their applications
Humanized anti-CD47 antibodies with specific CDR sequences address the side effects of conventional anti-CD47 antibodies, providing effective tumor therapy with reduced hemagglutination and enhanced antitumor activity in preclinical cancer models.
Patent Information
- Application Number
- JP2021510171
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-31
- Filing Date
- 2019-08-30
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2039-08-30
AI Technical Summary
Existing anti-CD47 antibodies used for tumor therapy often cause significant side effects such as hemagglutination, platelet degradation, and anemia, limiting their efficacy and safety in treating cancers like leukemia and lymphoma.
Development of anti-CD47 antibodies or antigen-binding fragments with specific heavy and light chain variable regions, including CDR sequences with at least 85% identity to predefined sequences, which are humanized to minimize hemagglutination and enhance antitumor activity while reducing immune rejection.
The humanized anti-CD47 antibodies effectively inhibit tumor growth with minimal hemagglutination, demonstrating significant antitumor effects in preclinical models without causing adverse effects on red blood cells, and show promise in treating various cancers including leukemia, lymphoma, and gastric cancer.
Smart Images

Figure 0007583707000011 
Figure 0007583707000012 
Figure 0007583707000013
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of antibody pharmaceutical technology, and in particular to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising an anti-CD47 antibody or an antigen-binding fragment thereof, and applications thereof. [Background technology]
[0002] CD47 protein, called integrity-associated protein (IAP), belongs to the IgG superfamily of five-transmembrane glycoproteins and is widely expressed in different tissues and cells. CD47 antibody can bind to its ligands TSP-1 or SIRPα to control different cell functions including cell migration, adhesion, apoptosis, axonal elongation, cell factor generation and T cell activation. SIRPα is a transmembrane protein containing a typical immunoreceptor tyrosine inhibitor sequence (ITIM) and is mainly expressed on the membrane surface of hematopoietic cells in the myelin system, such as macrophages, hematopoietic cells and dendritic cells. After binding to SIRPα, CD47 induces the phosphorylation of ITIMs, which then produces SHP-1 / SHP-2, which further inhibits the accumulation of myosin IIA at macrophage contacts, and finally inhibits the macrophage function of macrophage cells.
[0003] "Immune escape" of tumor cells is considered to be the main mechanism of tumor development, progression and drug resistance. High expression of CD47 molecules in tumor cells can interact with SIRPα on the surface of macrophages, significantly inhibiting the phagocytosis of macrophages and avoiding their uptake by macrophages. Inhibiting the binding of CD47 to SIRPα can eliminate the immune suppression or immune resistance caused by tumor cells and effectively kill tumor cells. This provides a very powerful theoretical basis for CD47 tumor immune targeting therapy. In recent years, many studies have been conducted at home and abroad on various therapies for the CD47 / SIRPα signaling pathway, such as CD47 antibodies, anti-SIRPα antibodies, recombinant SIRPα proteins, and bispecific antibodies. Among them, CD47 inhibitory antibodies are considered to be the most promising tumor treatment option. The efficacy of human CD47 blocking monoclonal antibodies has been demonstrated in multiple preclinical models, including lymphoma, bladder cancer, colon cancer, glioblastoma, breast cancer, acute lymphocytic leukemia, and acute myeloid leukemia. Furthermore, CD47 molecules are also expressed on red blood cells and platelets, and when antibodies block the interaction between CD47 and SIRPα, these cells lose the protection of the "don't ingest" signal and are further ingested by macrophages. Therefore, it is necessary to avoid side effects of CD47 antibodies, such as platelet degradation, red blood cell aggregation, decreased red blood cell count, and anemia, which should be considered when applying anti-CD47 antibodies. Therefore, there is a need to provide an anti-CD47 antibody or antigen-binding fragment thereof that has excellent anti-tumor activity and does not have significant hemagglutination activity. Summary of the Invention
[0004] In one aspect of the present invention, there is provided an anti-CD47 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region contains complementarity determining region 1 (HCDR1) of the heavy chain variable region, complementarity determining region 2 (HCDR2) of the heavy chain variable region and / or complementarity determining region 3 (HCDR3) of the heavy chain variable region, and the light chain variable region contains complementarity determining region 1 (LCDR1) of the light chain variable region, complementarity determining region 2 (LCDR2) of the light chain variable region and / or complementarity determining region 3 (LCDR3) of the light chain variable region.
[0005] In embodiments, the invention provides an anti-CD47 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region,
[0006] (1) the heavy chain variable region (a1) the amino acid sequence represented by SEQ ID NO: 1, 2, or 3; (a2) the amino acid sequences represented by SEQ ID NOs: 10, 2 and 11; (a3) the amino acid sequences represented by SEQ ID NOs: 4, 5 and 6; (a4) the amino acid sequences shown in SEQ ID NOs: 7, 8 and 9, and (a5) comprising HCDR1, HCDR2 and HCDR3 selected from the group consisting of CDRs having at least 85% identity to the amino acid sequence shown in (a1), (a2), (a3) or (a4); (2) the light chain variable region (a6) the amino acid sequences represented by SEQ ID NOs: 12, 13, and 14; (a7) the amino acid sequences represented by SEQ ID NOs: 15, 16, and 17; (a8) the amino acid sequences represented by SEQ ID NOs: 18, 19, and 20; (a9) comprises an LCDR1, an LCDR2 and an LCDR3 selected from the group consisting of CDRs having at least 85% identity to the amino acid sequence shown in (a6), (a7) or (a8).
[0007] In a specific embodiment, the invention provides an anti-CD47 antibody or antigen-binding fragment comprising a heavy chain variable region, in which the HCDR1, HCDR2 and HCDR3 are CDRs having at least 85% identity to the amino acid sequences set forth in SEQ ID NOs:1, 2 and 3, or SEQ ID NOs:1, 2 and 3, respectively, and a light chain variable region, in which the LCDR1, LCDR2 and LCDR3 are CDRs having at least 85% identity to the amino acid sequences set forth in SEQ ID NOs:12, 13 and 14, or SEQ ID NOs:12, 13 and 14, respectively. In a specific embodiment, the invention provides an anti-CD47 antibody or antigen-binding fragment comprising a heavy chain variable region, in which the HCDR1, HCDR2 and HCDR3 are CDRs having at least 85% identity to the amino acid sequences set forth in SEQ ID NOs:10, 2 and 11, or SEQ ID NOs:10, 2 and 11, respectively, and a light chain variable region, in which the LCDR1, LCDR2 and LCDR3 are CDRs having at least 85% identity to the amino acid sequences set forth in SEQ ID NOs:12, 13 and 14, or SEQ ID NOs:12, 13 and 14, respectively. In a specific embodiment, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region in which the HCDR1, HCDR2 and HCDR3 are CDRs having at least 85% identity to the amino acid sequences shown in SEQ ID NOs:4, 5 and 6 or SEQ ID NOs:4, 5 and 6, respectively, and a light chain variable region in which the LCDR1, LCDR2 and LCDR3 are CDRs having at least 85% identity to the amino acid sequences shown in SEQ ID NOs:15, 16 and 17 or SEQ ID NOs:15, 16 and 17, respectively. In a specific embodiment, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region in which the HCDR1, HCDR2 and HCDR3 are CDRs having at least 85% identity to the amino acid sequences shown in SEQ ID NOs:7, 8 and 9 or SEQ ID NOs:7, 8, and 9, respectively, and a light chain variable region in which the LCDR1, LCDR2 and LCDR3 are CDRs having at least 85% identity to the amino acid sequences shown in SEQ ID NOs:18, 19, and 20 or SEQ ID NOs:18, 19, and 20, respectively. In some specific embodiments, the anti-CD47 antibodies, or antigen-binding fragments thereof, of the invention are monoclonal antibodies, or antigen-binding fragments thereof. In some specific embodiments, the anti-CD47 antibody or antigen-binding fragment thereof of the invention is a murine antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, or a humanized antibody or antigen-binding fragment thereof. In some specific embodiments, the invention provides an anti-CD47 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, (1) The amino acid sequence of the heavy chain variable region is (b1) the amino acid sequences represented by SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:27; (b2) an amino acid sequence in which one or more amino acids are substituted, deleted or added to the amino acid sequence shown in (b1) and which has the same or similar function as the amino acid sequence shown in (b1); and (b3) an amino acid sequence having at least 80% identity to the amino acid sequence shown in (b1); (2) The amino acid sequence of the light chain variable region is (b4) the amino acid sequence represented by SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 28; (b5) an amino acid sequence in which one or more amino acids are substituted, deleted or added to the amino acid sequence shown in (b4), and which has the same or similar function as the amino acid sequence shown in (b4); (b6) An anti-CD47 antibody or antigen-binding fragment thereof, comprising an amino acid sequence having at least 80% identity to the amino acid sequence shown in (b4).
[0008] In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:21, an amino acid sequence of SEQ ID NO:21 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:21, or an amino acid sequence having at least 85% identity to SEQ ID NO:21, and the amino acid sequence of the light chain variable region is SEQ ID NO:24, an amino acid sequence of SEQ ID NO:24 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:24, or an amino acid sequence having at least 85% identity to SEQ ID NO:24. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:22, an amino acid sequence of SEQ ID NO:22 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:22, or an amino acid sequence having at least 85% identity to SEQ ID NO:22, and the amino acid sequence of the light chain variable region is SEQ ID NO:25, an amino acid sequence of SEQ ID NO:25 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:25, or an amino acid sequence having at least 85% identity to SEQ ID NO:25. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:23, an amino acid sequence of SEQ ID NO:23 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:23, or an amino acid sequence having at least 85% identity to SEQ ID NO:23, and the amino acid sequence of the light chain variable region is SEQ ID NO:26, an amino acid sequence of SEQ ID NO:26 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:26, or an amino acid sequence having at least 85% identity to SEQ ID NO:26. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:27, an amino acid sequence of SEQ ID NO:27 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:27, or an amino acid sequence having at least 85% identity to SEQ ID NO:27, and the amino acid sequence of the light chain variable region is SEQ ID NO:24, an amino acid sequence of SEQ ID NO:24 with one or more amino acid substitutions, deletions or additions and having the same function as SEQ ID NO:24, or an amino acid sequence having at least 85% identity to SEQ ID NO:24. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:23, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:23 and having the same function as SEQ ID NO:23, or an amino acid sequence having at least 85% identity to SEQ ID NO:23, and the amino acid sequence of the light chain variable region is SEQ ID NO:28, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:28 and having the same function as SEQ ID NO:28, or an amino acid sequence having at least 85% identity to SEQ ID NO:28. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:21, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:21 and having the same function as SEQ ID NO:21, or at least 85% identity to SEQ ID NO:21, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:1, 2 and 3; and the amino acid sequence of the light chain variable region is SEQ ID NO:24, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:24 and having the same function as SEQ ID NO:24, or at least 85% identity to SEQ ID NO:24, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:12, 13 and 14. In a specific embodiment, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:22, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:22 and having the same function as SEQ ID NO:22, or at least 85% identity to SEQ ID NO:22, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:4, 5 and 6; and the amino acid sequence of the light chain variable region is SEQ ID NO:25, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:25 and having the same function as SEQ ID NO:25, or at least 85% identity to SEQ ID NO:25, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:15, 16 and 17. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:23, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:23 and having the same function as SEQ ID NO:23, or the amino acid sequence having at least 85% identity to SEQ ID NO:23, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:7, 8 and 9, and the amino acid sequence of the light chain variable region is SEQ ID NO:26, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:26 and having the same function as SEQ ID NO:26, or the amino acid sequence having at least 85% identity to SEQ ID NO:26, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:18, 19 and 20. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:27, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:27 and having the same function as SEQ ID NO:27, or an amino acid sequence having at least 85% identity to SEQ ID NO:27 and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:1, 2 and 11, and the amino acid sequence of the light chain variable region is SEQ ID NO:24, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:24 and having the same function as SEQ ID NO:24, or an amino acid sequence having at least 85% identity to SEQ ID NO:24 and having the same amino acid sequence as SEQ ID NO:24, or an amino acid sequence having at least 85% identity to SEQ ID NO:24 and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:12, 13 and 14. In some specific embodiments, the present invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:23, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:23 and having the same function as SEQ ID NO:23, or an amino acid sequence having at least 85% identity to SEQ ID NO:23 and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:7, 8 and 9, and the amino acid sequence of the light chain variable region is SEQ ID NO:28, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:28 and having the same function as SEQ ID NO:28, or an amino acid sequence having at least 85% identity to SEQ ID NO:28 and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:18, 19 and 20. In some specific embodiments, the anti-CD47 antibodies of the invention are murine antibodies and have a heavy chain variable region that comprises murine IgG1, IgG2, IgG3, IgG4 or a variant thereof, and an amino acid sequence of a light chain variable region that is murine-derived k chain or a variant thereof. In some preferred embodiments, the murine anti-CD47 antibodies of the invention further comprise a heavy chain constant region of murine IgG1 or IgG2 or variants thereof, and a light chain variable region of murine-derived k chain and variants thereof. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody, or antigen-binding fragment thereof, comprising: (1) The amino acid sequence of the heavy chain variable region is (c1) the amino acid sequence represented by SEQ ID NO: 29, SEQ ID NO: 30, or SEQ ID NO: 31; (c2) an amino acid sequence in which one or more amino acids are substituted, deleted or added to the amino acid sequence shown in (c1) and which has the same or similar function as the amino acid sequence shown in (c1); and (c3) an amino acid sequence having at least 80% identity to the amino acid sequence shown in (c1); (2) The amino acid sequence of the light chain variable region is (c4) the amino acid sequence represented by SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34; (c5) an amino acid sequence in which one or more amino acids are substituted, deleted or added to the amino acid sequence shown in (c4) above, and which has the same or similar function as the amino acid sequence shown in (c4); and (c6) A humanized anti-CD47 antibody or an antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment being selected from an amino acid sequence having at least 80% identity to the amino acid sequence shown in (c4). In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:29, an amino acid sequence of SEQ ID NO:29 in which one or more amino acids have been substituted, deleted or added and which has the same function as SEQ ID NO:29, or an amino acid sequence having at least 85% identity to SEQ ID NO:29, and the amino acid sequence of the light chain variable region is SEQ ID NO:32, an amino acid sequence of SEQ ID NO:32 in which one or more amino acids have been substituted, deleted or added and which has the same function as SEQ ID NO:32, or an amino acid sequence having at least 85% identity to SEQ ID NO:32. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:30, an amino acid sequence of SEQ ID NO:30 in which one or more amino acid substitutions, deletions or additions have the same function as SEQ ID NO:30, or an amino acid sequence having at least 85% identity to SEQ ID NO:30, and the amino acid sequence of the light chain variable region is SEQ ID NO:33, an amino acid sequence of SEQ ID NO:33 in which one or more amino acid substitutions, deletions or additions have the same function as SEQ ID NO:33, or an amino acid sequence having at least 85% identity to SEQ ID NO:33. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:31, an amino acid sequence in which one or more amino acids have been substituted, deleted or added to SEQ ID NO:31 and which has the same function as SEQ ID NO:31, or an amino acid sequence having at least 85% identity to SEQ ID NO:31, and the amino acid sequence of the light chain variable region is SEQ ID NO:34, an amino acid sequence in which one or more amino acids have been substituted, deleted or added to SEQ ID NO:34 and which has the same function as SEQ ID NO:34, or an amino acid sequence having at least 85% identity to SEQ ID NO:34. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:29, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:29 and having the same function as SEQ ID NO:29, or at least 85% identity to SEQ ID NO:29, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:10, 2 and 11, and the amino acid sequence of the light chain variable region is SEQ ID NO:32, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:32 and having the same function as SEQ ID NO:32, or at least 85% identity to SEQ ID NO:32, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:12, 13 and 14. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:30, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:30 and having the same function as SEQ ID NO:30, or at least 85% identity to SEQ ID NO:30, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NOs:4, 5 and 6, and the amino acid sequence of the light chain variable region is SEQ ID NO:33, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:33 and having the same function as SEQ ID NO:33, or at least 85% identity to SEQ ID NO:33, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NOs:15, 16 and 17. In some specific embodiments, the present invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO:31, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:31 and having the same function as SEQ ID NO:31, or the amino acid sequence having at least 85% identity to SEQ ID NO:31, and the HCDR1, HCDR2 and HCDR3 are the amino acid sequences shown in SEQ ID NO:7, 8 and 9, and the amino acid sequence of the light chain variable region is SEQ ID NO:34, an amino acid sequence having one or more amino acid substitutions, deletions or additions to SEQ ID NO:34 and having the same function as SEQ ID NO:34, or the amino acid sequence having at least 85% identity to SEQ ID NO:34, and the LCDR1, LCDR2 and LCDR3 are the amino acid sequences shown in SEQ ID NO:18, 19 and 20. In some embodiments, the invention provides a humanized anti-CD47 antibody or antigen-binding fragment thereof, wherein the heavy chain comprises a heavy chain variable region of a humanized IgG1, IgG2, IgG3, IgG4, or variant thereof, and the light chain comprises a light chain constant region of a humanized k chain, lambda chain, or variant thereof. In one preferred embodiment of the invention, the mouse CD47 antibody or antigen-binding fragment thereof further comprises a light chain constant region of a mouse k chain, λ chain or a variant thereof, and / or a heavy chain constant region of a mouse IgG1, IgG2, IgG3, IgG4 or a variant thereof.
[0009] In one preferred embodiment of the invention, the antibody light chain of the chimeric anti-CD47 antibody or antigen-binding fragment thereof further comprises a light chain constant region of mouse k chain, lambda chain or a mutated sequence thereof, and the antibody heavy chain of the chimeric anti-CD47 antibody or antigen-binding fragment thereof further comprises a heavy chain constant region of mouse IgG1, IgG2, IgG3 or IgG4 or a mutated sequence thereof, preferably a human IgG1 or IgG2 heavy chain variable region, or an IgG4 constant region that significantly reduces ADCC (antibody-dependent cell-mediated cytotoxicity) toxicity after amino acid mutation. In some specific embodiments, the humanized anti-CD47 antibody or antigen-binding fragment thereof of the invention further comprises a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4 or variants thereof, and a light chain constant region of human k chain, lambda chain or variants thereof. In some preferred embodiments, the humanized anti-CD47 antibody or antigen-binding fragment thereof of the invention further comprises a heavy chain constant region of human IgG1, IgG2 or variants thereof, and a light chain constant region of human k chain or variants thereof. In some embodiments, the invention provides an anti-CD47 antibody or antigen-binding fragment thereof, wherein the antigen-binding fragment is a Fab, Fv, sFv, or F(ab)2. Another aspect of the invention provides an isolated nucleic acid encoding an anti-CD47 antibody, or antigen-binding fragment thereof, of the invention. In some specific embodiments, in the isolated nucleic acid of the invention, the nucleotide sequence encoding the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO:35 or SEQ ID NO:36 or SEQ ID NO:37, and the nucleotide sequence encoding the amino acid sequence of the light chain variable region is set forth in SEQ ID NO:38 or SEQ ID NO:39 or SEQ ID NO:40. In one specific embodiment, in the isolated nucleic acid of the present invention, the nucleotide sequence encoding SEQ ID NO:29 of the heavy chain variable region is set forth in SEQ ID NO:35, and the nucleotide sequence encoding SEQ ID NO:32 of the light chain constant region is set forth in SEQ ID NO:38. In one specific embodiment, in the isolated nucleic acid of the invention, the nucleotide sequence encoding SEQ ID NO:30 of the heavy chain variable region is represented by SEQ ID NO:36, and the nucleotide sequence encoding SEQ ID NO:33 of the light chain constant region is represented by SEQ ID NO:39. In one specific embodiment, in the isolated nucleic acid of the invention, the nucleotide sequence encoding SEQ ID NO:31 of the heavy chain variable region is represented by SEQ ID NO:37, and the nucleotide sequence encoding SEQ ID NO:34 of the light chain constant region is represented by SEQ ID NO:40. In another aspect of the invention, there is provided an expression vector for expressing an anti-CD47 antibody or antigen-binding fragment thereof of the invention. The expression vector of the invention comprises an isolated nucleic acid molecule of the invention. In another aspect of the invention, there is provided a host cell transformed with the above-described expression vector. In some embodiments, the host cell of the invention is selected from a prokaryotic cell and a eukaryotic cell. In some embodiments, the host cell is a bacterium, preferably E. coli. In other preferred embodiments, the host cell is a mammalian cell. In another aspect of the invention, there is provided a method for producing an anti-CD47 antibody, or antigen-binding fragment thereof, of the invention, comprising the steps of expressing the antibody in said host cell and isolating said antibody from the host cell. In another aspect of the invention, a pharmaceutical composition is provided that includes a humanized anti-CD47 antibody or antigen-binding fragment thereof of the invention and a pharma- ceutically acceptable carrier. In some embodiments, the invention provides a pharmaceutical composition that includes a humanized anti-CD47 antibody or antigen-binding fragment thereof of the invention, and further includes other active ingredients, such as other antibodies, targeting agents, etc. In some embodiments, the pharma- ceutically acceptable carrier is selected from antioxidants, polypeptides, proteins, hydrophilic primers, amino acids, sugars, chelating agents, alditols, and ion surface activators. In a specific embodiment, the pharma-ceutically acceptable carrier is a buffer solution. In another specific embodiment, the pharma-ceutically acceptable carrier is a liposome. The humanized anti-CD47 antibody or antigen-binding fragment thereof of the present invention is mixed with a pharma- ceutical acceptable carrier, diluent or excipient to be administered orally or parenterally and prepared as a pharmaceutical preparation. The pharmaceutical administration route is oral, intradermal, intramuscular, intraperitoneal, intravenous, intracerebral, intraocular, intratracheal, subcutaneous or intranasal. The preparation can be administered by any route. For example, it can be administered by drip injection or bolus injection, or by a route absorbed through epithelium or skin mucosa (e.g., oral mucosa or rectum). The pharmaceutical administration is systemic or local. The preparation can be prepared by a method known in the art and contains a carrier, diluent or excipient commonly used in the pharmaceutical field. Another aspect of the invention provides a method of inhibiting CD47 activity comprising administering to a subject in need thereof an anti-CD47 antibody or antigen-binding fragment thereof of the invention, or a pharmaceutical composition of the invention. In another aspect of the present invention, there is provided a use of the anti-CD47 antibody or antigen-binding fragment thereof or the pharmaceutical composition of the present invention in the preparation of a CD47 activity inhibitor. In some embodiments, the CD47 activity inhibitor is used for the treatment of leukemia, lymphoma, breast cancer, lung cancer, gastric cancer, colon cancer, esophageal cancer, ovarian cancer, cervical cancer, kidney cancer, bladder cancer, pancreatic cancer, glioma, and / or melanoma. In some embodiments, the present invention provides a use of the anti-CD47 antibody or antigen-binding fragment thereof or the pharmaceutical composition of the present invention in the manufacture of an antitumor drug. Preferably, the tumor is selected from leukemia, lymphoma, breast cancer, lung cancer, gastric cancer, colon cancer, esophageal cancer, ovarian cancer, cervical cancer, kidney cancer, bladder cancer, pancreatic cancer, glioma, and / or melanoma. The anti-CD47 antibody or its antigen-binding fragment provided by the present invention has significant antitumor effect, significantly inhibits tumor growth, has no significant hemagglutination activity, greatly reduces the immunogenicity of humanized antibodies, and effectively eliminates the rejection reaction of the human immune system to exogenous monoclonal antibodies. It can be used in the preparation of drugs for treating various tumor diseases, and has broad market prospects.
[0010] definition Unless otherwise defined, the meanings of scientific and technical terms used herein are those commonly understood by those of ordinary skill in the art. The nomenclature and techniques used in cell and tissue culture, molecular biology, protein, oligonucleotide and polynucleotide, and hybridization described herein are applications commonly known in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, tissue culture, and transformation (electroporation, liposomal transfection). Enzymatic reactions and purification techniques are performed according to manufacturer's instructions, methods commonly used in the art, or described herein. The techniques and methods are generally used as described in several comprehensive and relatively specific references well known in the art and cited and discussed herein. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The nomenclature, laboratory methods, and techniques used in analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. In the present invention, the term "at least 80% identity" refers to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity. In the present invention, the term "at least 85% sequence identity" refers to at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identity. In some preferred embodiments, sequence identity according to the present invention means at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%. The sequence comparison and percent identity determination between two sequences is performed by the BLASTN / BLASTP algorithm at the National Center For Biotechnology Institute website. In an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are arranged in three-dimensional space in corresponding positions to each other to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of the antigen to be bound, and each of the three hypervariable regions of the heavy and light chains is called a "complementarity determining region" or "CDR". The amino acid ratio for each domain is defined by Kabat, "Sequences of Immunologically Interesting Proteins" (National Institutes of Health, Bethesda, Maryland (1987 and 1991)) or Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989). The "antigen-binding fragment" according to the present invention includes Fab fragments, Fab' fragments, F(ab')2 fragments with antigen-binding activity, and Fv fragments and scFv fragments with human CD47 binding activity. Fv fragments have the heavy and light chain variable regions of an antibody, but lack the constant region, and are the smallest antibody fragments with all antigen-binding sites. In general, Fv antibodies further include a polypeptide linker between the VH and VL domains, and can form a structure required for antigen binding. Two antibody variable regions are linked as a single polypeptide by different linkers, and are called single-chain antibodies or single-chain Fvs (scFvs). An antibody according to the present invention is an immunoglobulin or an immunologically active part thereof, i.e. a molecule that specifically binds to an antigen-binding site of an antigen (provokes an immune response). "Specific binding" refers to an antibody that reacts with one or more epitopes of an antigen, but does not react with other polypeptides or has a low affinity (Kd>10 -6 ) to another polypeptide. Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, dAb (domain antibody), single chain, Fab, Fab' and F(ab')2 fragments, Fv, scFv and Fab libraries. A monoclonal antibody (mAb) is an antibody obtained from a clone derived from a single antibody-producing cell line, which may be, but is not limited to, a eukaryotic, prokaryotic or bacteriophage cell line. Monoclonal antibodies or antigen-binding fragments may be obtained by hybridoma technology, recombinant technology, bacteriophage display technology, and synthetic technology, such as recombinantly by CDR grafting or other conventional techniques. The "mouse antibody" of the present invention is a monoclonal antibody against human CD47, produced according to the knowledge and techniques of the art. During production, a subject is injected with CD47 antigen, and then hybridomas expressing antibodies with the desired sequence or functional characteristics are isolated. The "chimeric antibody" according to the present invention is an antibody formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can reduce the immune response induced by mouse antibodies. To establish a chimeric antibody, a hybridoma secreting a specific monoclonal antibody derived from a mouse is established, then the variable region gene is cloned from the mouse hybridoma cell, and if necessary, the constant region gene of a human antibody is cloned, and the mouse variable region gene is linked with the human constant region gene to form a chimeric gene, which is then inserted into a human vector, and finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system.
[0011] The "humanized antibodies" according to the present invention, also called CDR-grafted antibodies, are produced by grafting mouse CDR sequences onto the human antibody framework regions (FR). Such framework region sequences can be obtained from public DNA databases or from published references, for example from the ImMunoGeneTics (IMGT) website http: / / imgt.cines.fr, or from the Immunosphere Proteins Journal, 2001 ISBN 012441351. [Brief description of the drawings]
[0012] [Figure 1] FIG. 1 shows the results of a binding activity assay (ELISA) between humanized anti-CD47 antibodies and monkey CD47. [Diagram 2] FIG. 2 shows the results of a binding activity assay (ELISA) between a humanized anti-CD47 antibody and human CD47. [Diagram 3] FIG. 3 shows the results of a binding activity assay (ELISA) between a humanized anti-CD47 antibody and cell surface human CD47. [Figure 4] FIG. 4 shows the results of a hemagglutination experiment, where RBC: positive control, PBS: blank control. [Diagram 5] FIG. 5 shows the results of an experiment measuring the blocking activity of humanized anti-CD47 antibodies by FACS. [Figure 6]FIG. 6 shows the results of an antitumor test using the humanized anti-CD47 antibody Hu34-39-PE in a human gastric cancer NUGC-4 xenograft tumor model. [Figure 7] FIG. 7 shows the results of an antitumor test using the humanized anti-CD47 antibody Hu26T-31-PE in a human gastric cancer NUGC-4 xenograft tumor model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The following representative examples are used to better illustrate the present invention, without limiting the scope of protection of the present invention. The experimental methods specified in the following examples without conditions are usually performed according to general conditions, such as the Cold Spring Harbor Antibody Technology Experiment Manual, Molecular Cloning Manual, etc., or according to the conditions recommended by the manufacturers of raw materials and products. All materials and reagents used in the examples are commercially available unless otherwise specified.
[0014] Example 1 Preparation of antigen protein and positive control antibody
[0015] 1. Construction of expression vectors for antigen protein and positive control antibody (1) Construction of expression vector for antigen protein A gene fragment encoding the full-length CD47 protein was synthesized, and the amino acid sequence was designed as shown in SEQ ID NO:41, and then cloned into the eukaryotic expression plasmid pTargeT to obtain the expression plasmid pTargeT-CD47. The amino acid sequence of the extracellular domain of human CD47 protein was fused with the amino acid sequence of hIgG1-Fc or his tag, and the amino acid sequences were designed as shown in SEQ ID NO: 42 and SEQ ID NO: 43, respectively. After codon optimization of the above amino acid sequences, the tagged CD47 protein extracellular domain gene fragments CD47-hFc and CD47-his were synthesized and cloned into the eukaryotic expression plasmid pHR, respectively, to obtain the expression plasmids pHR-CD47-hFc and pHR-CD47-his. The amino acid sequence of the extracellular domain of human CD47 protein was fused with the mIgG1-Fc amino acid sequence, and the amino acid sequence was designed as shown in SEQ ID NO: 44. After codon optimization of the above amino acid sequence, the complete expression plasmid pcDNA3.1(+)-TPA-CD47-mIgG1-Fc was synthesized. The sequence of SIRPα is shown in SEQ ID NO:45, and after codon optimization of said sequence, the complete expression plasmid pcDNA3.1(+)-SIRPα-myc-His was synthesized.
[0016] (2) Construction of expression vector for positive control antibody The antibody AB6.12-IgG4P (herein referred to as AB06.12-4P) disclosed in patent application WO2013 / 119714 is used as a positive control antibody. The amino acid sequence of AB06.12-4P is as follows: AB06.12-4P heavy chain variable region: SEQ ID NO:46, AB06.12-4P light chain variable region: SEQ ID NO:47. The amino acid sequence corresponding to the antibody sequence was artificially codon-optimized to obtain the heavy and light chain amino acid sequence expression plasmids pcDNA3.1(+)-SHC025-hG4 and pcDNA3.1(+)SHC025-hk of the positive control antibody AB06.12-4P. The heavy chain gene fragment was cloned into the eukaryotic expression plasmid pHR containing the IgG light chain constant region to obtain the heavy chain eukaryotic expression plasmid pHR-SHC025-hG4-4PE of AB06.12-4P. The light chain expression plasmid is pcDNA3.1(+)-SHC025-hk.
[0017] 2. Expression and purification of antigen protein and positive control antibody (1) Construction of stable transgenic cell lines expressing antigen proteins Eukaryotic expression plasmid pTargeT-CD47 was transfected into CHO-K1 cells (Shanghai Institute of Cell Biology, Chinese Academy of Chemical Sciences) by electroporation with a square pulse of 160V and 15msec, and then cultured in an incubator set at 37℃ and 5%CO2. After 24 hours, pressure culture was performed using a medium containing 500ug / ml G418. After 16 days, the pool positive rate was detected by FACS, and the cells after plasmid electroporation were plated (cell density 1x10 6 cells / ml, 100ul / well), PE mouse anti-human CD47 antibody (BD, 556046) was used to incubate with the cells, the average value was read at 585nm wavelength using a flow cytometer (BD, FACSJazz), data analysis was performed using GraphPad, the positive cell lines were subcloned, and a cloned CHO-K1 cell line expressing high levels of CD47 molecule was selected and designated as CHO-K1-E5. (2) Expression of tagged antigen protein and positive control antibody A 1L cell culture flask with a density of 0.5x10 6293F cells were seeded at 10 ... 250μg of plasmid awaiting transfection was taken and added with 8.5ml of FreeStyle 293 expression medium, mixed evenly, where the plasmids pHR-CD47-hFc, pHR-CD47-his, pcDNA3.1(+)-TPA-CD47-mIgG1-Fc, and pcDNA3.1(+)-SIRPα-myc-His for expressing tagged antigen proteins were transfected, respectively, and the positive control antibody AB06.12-4P heavy chain plasmid pHR-SHC025-hG4-4PE and light chain plasmid pcDNA3.1(+)-SHC025-hk were co-transfected. The mixture of PEI and FreeStyle 293 expression medium was added to the plasmid, mixed evenly, and then the cell culture was added and cultured in a humidified CO2 incubator at 37℃, 8% CO2. On the first and third days after cell transfection, nutrients were added to the cells, with 2.5 ml of glutamine (concentration of mother liquor: 200 mM) and 5 ml of glucose (concentration of mother liquor: 180 g / L) added per bottle. When cell viability was reduced to 65%-75%, the cell supernatant was collected. The cell culture was centrifuged at 1500 rpm for 5 min, the supernatant was collected, and then centrifuged at 8000 rpm for 20 min, and the supernatant was collected. (3) Purification using affinity chromatography columns Using AKTA (GE, AKTA pure-150), different affinity chromatography columns were selected depending on the properties of the protein and purified (affinity chromatography columns applicable to different proteins are shown in Table 1). Specifically, the purification procedure is as follows.
[0018] [Table 1] Cleaning: The equipment and pipelines were cleaned with ultrapure water for 2 min at a flow rate of 10 mL / min, and the chromatography system was cleaned with 0.1 M NaOH. Column connection: The chromatography column is connected to the chromatography apparatus and washed with ultrapure water for 5 min, then with 0.1 M NaOH for 30 min, with a retention time of 5 min. Equilibration: Equilibrated with 20 mM PB + 0.15 M NaCl, pH 7.2 for 5 CV (column volumes). Loading: Cell culture supernatant was sampled and the retention time was 5 min. Re-equilibration: Equilibrate for 5 CV with 20 mM PB + 0.15 M NaCl, pH 7.2. Elution: Elute with 50 mM acetic acid, pH = 3.4, retention time 5 min. Collection was started when UV was 280 ~ 50 mAu, and stopped when it dropped to about 50 mAu. The pH of the sample was adjusted to 7.0 with 1 M Tris-HCl, pH 9.0. Re-equilibration: Equilibrate with 20 mM PB + 0.15 M NaCl, pH 7.2 for 3 CV with a hold time of 5 min. Online washing: Wash with 0.1 M NaOH for 30 min, retention time 5 min. Washing and storage: After washing with purified water for 10 minutes, the plate was washed with 20% alcohol for 2 CV.
[0019] Example 2: Preparation of monoclonal antibodies 1. Preparation of hybridoma monoclonals (1) Animal immunity SJL experimental mice were immunized with differently tagged anti-CD47 antigen proteins in adjuvant, with 50ug of antigen in the early stage and 25ug of antigen in the late stage. The immune adjuvant may be Quick Antibody-Mouse5W (Beijing Boaolong Immunotechnology Co., Ltd.) or Titer Max (Sigma) and CpG (Jinsir Biotechnology Co., Ltd.) / Alum (thermo) adjuvant interval. The samples of CD47 antigen proteins with different tags were added drop by drop to the adjuvant solution, vortexed dropwise to mix thoroughly, and the dose of the adjuvant was selected with reference to the specification. After thorough mixing to form a water-in-oil emulsion, the SJL mice were immunized. The cell lines used for the analysis of high-level expression of CD47, such as CCRF-CEM and CHO-K1-E5, were also used for immunization of mice. Cultured human acute lymphocytic leukemia cells (CCRF-CEM) and CHO-K1-E5 positive single cells obtained in Example 1 were treated by trypsin digestion, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, the cell pellet was resuspended in PBS, and counted by cell counter for sampling. The remaining sample was centrifuged at 1000 rpm for 5 min, the supernatant was discarded, the cell pellet was resuspended in PBS, an appropriate amount of PBS was added, and 1x10 8 The experimental mice were cultured at 1x10 cells / ml. 7 The mice were immunized with IgG4-associated leukemia virus (LEV)-associated leukemia virus (LEV). The immunization patterns are shown in Table 2. [Table 2]
[0020] (2) Hybridoma fusion Acquisition and preparation of spleen cells: Booster mice were sacrificed and immersed in 75% alcohol. The spleen was dissected and removed, ground with a pestle, and filtered through a cell sieve to prepare a single cell suspension. The spleen cell suspension was centrifuged at 2000 rpm for 5 min, and the supernatant was discarded. 2 ml of red blood cell lysis solution was added to dissolve red blood cells at room temperature for 2 min, PBS was added to 20 ml, and centrifuged at 1500 rpm for 7 min, after which the supernatant was discarded, resuspended, and the number of live cells was counted. Sp2 / 0 cells in a culture bottle were collected, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, resuspended, and the number of live cells was counted. The cells were mixed at a ratio of spleen cells:Sp2 / 0 cells = 1:1, centrifuged at 1500 rpm for 7 min, and the supernatant was discarded. The cells were resuspended in 20 mL of electroporation buffer and centrifuged at 1500 rpm for 7 min. The supernatant was discarded and repeated once. Cell concentration is 2 x 10 7 The cells were resuspended in an appropriate amount of electroporation buffer to approximately 4 × 10 cells / mL. 9 mL of the cell suspension was added to the electroporation fusion tank and fused. After fusion, the cell suspension was transferred to 15 mL of RPMI 1640 complete medium containing 20% FBS and left at room temperature for 20 min. The fused cells were resuspended in RPMI 1640 medium containing 1 × HAT, 1 × BIOMYC3, and 20% FBS. The cell volume was approximately 4 × 10 4 The cell suspension was added to some 96-well plates at 100 μL / well so that the cells were 100 cells / well, and the plates were cultured in an incubator at 37° C. After 5 days, RPMI 1640 complete medium (containing 20% FBS, 1× HAT, and 1× BIOMYC-3) was added at 100 μL / well.
[0021] (3) Screening of hybridoma and subclone supernatants After one week of fusion, the cell supernatant was taken out, and the hybridoma supernatants that could bind to CD47-his protein or CD47 on the cell surface were screened by ELISA, and CD47-his was used to screen for antibodies against CD47 instead of hFc and mFc. The ability of the hybridoma supernatants to inhibit CD47-SIRPα interaction was then analyzed by ELISA. SIRPα-myc-his was coated on an ELISA plate, and a mixture of recombinant human protein CD47-hFc and hybridoma supernatants was added and incubated for 2 h, and HRP-labeled anti-human IgG Fc specific antibody (Jackson Immuno Research) was added and incubated for 1 h, and the absorbance value at 450 nm was detected by a microplate reader. The hybridoma parent clones with binding and inhibitory abilities obtained by screening were expanded and their binding and inhibitory activities were re-measured, and the hybridoma positive clones with binding and inhibitory abilities were screened again. The positive cell lines were subcloned using the limiting dilution method, and after one week of culture, the binding activity of the subclone supernatants to CD47 molecules and the inhibitory activity of CD47-SIRPα interaction were detected by ELISA, and three double-positive cell lines were obtained, named SHC025-26, SHC025-34, and SHC025-58, respectively.
[0022] 2. Identification of subtypes The antibody subtypes were identified by referring to the instruction manual for the mouse antibody subtype identification kit SBA Clonotyping System-C57BL / 6-HRP (SouthernBiotech, model number: 5300-05B). The results are shown in Table 3. [Table 3]
[0023] 3. Preparation of monoclonal antibodies As shown by the activity analysis of the subclone supernatants, the parent clones of the monoclonal antibodies SHC025-26, SHC025-34, and SHC025-58 were identified and expanded. The culture conditions were 1640 medium containing 10% fetal bovine serum, 1x NAEE, 1x sodium pyruvate, and 1% penicillin-streptomycin double antibody. When the cell confluence was more than 80%, the cells were subcultured and expanded. When the culture reached about 50 ml, the supernatant was collected and the antibodies were purified. The obtained antibodies were confirmed to be of good purity by SDS-PAGE gel electrophoresis.
[0024] 4. Monoclonal antibody sequencing Positive hybridoma cells from the subclone were expanded and an appropriate amount of cells was harvested. Total RNA was extracted according to the RNeasy Plus Mini Kit (Qiagen, 74134) instructions, and the first strand of cDNA was synthesized using the Prime Script 1st strand cDNA Synthesis Kit (Takara, 6110A) reverse transcription kit. Design specific primers (5' end contains homology arms for homologous recombination with eukaryotic expression vector) according to the variable regions of mouse antibody subtypes, and perform PCR amplification of antibody variable region genes using cDNA as template to obtain gene fragments of light and heavy chain variable regions of mouse antibodies, and design primers (References: 1. Anke Krebber, Susanne Bornhauser, Jorg Burmester et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. Journal of Immunological Methods, 1997, 201:35-55. 2. DNA sequencing was performed using a genomic DNA sequencing kit (see TIFF0007583707000004.tif5140sequencing as a method for hybridoma cell-line authentication, 2008, 78:1071-1078) to obtain the DNA sequence, and the sequencing results are shown in Table 4. [Table 4]
[0025] Example 4 Construction of chimeric antibodies After purification (see Example 1 for purification procedure), the mouse antibody light chain and heavy chain variable region gene fragments were co-transformed with linearized eukaryotic expression plasmids containing human antibody light chain or heavy chain constant region, respectively, into E. coli DH5α responsive cells, and the mixture was evenly spread on the surface of an agar plate containing the corresponding antibiotic. After overnight incubation in a constant temperature incubator at 37°C, several single colonies were selected for DNA sequencing, and the chimeric antibodies with the correct sequences were designated as SHC025-26CHI, SHC025-34CHI, and SHC025-58CHI, respectively. Positive clones with the correct sequence were inoculated into 2xYT liquid medium containing the corresponding antibiotics and cultured at 37°C with shaking for more than 12 hours. The cells were then harvested and the plasmids were extracted to obtain the plasmids for expressing the light and heavy chains of the chimeric antibody. The concentration and purity of the plasmids were detected using a nucleic acid quantitative analyzer. The chimeric antibody was transfected into HEK293E cells, expressed and purified to obtain large amounts of antibody, and purity detection, activity analysis and affinity detection were performed. Sequencing revealed that the 118th position of the heavy chain CDR of SHC025-26 and the 56th position of the light chain CDR of SHC025-58 each contained one cysteine, and the cysteines in the CDR regions randomly paired with other cysteines on the antibody molecule during expression and were oxidized to form disulfide bridges, which greatly affected the purity of the antibody. To solve this problem, the amino acid sequences of SHC025-26CHI and SHC025-58CHI were modified as follows: C118 of the SHC025-26CHI heavy chain was mutated to T, which is designated as SHC025-26CHI-T; C56 of the SHC025-58CHI light chain was mutated to A, which is designated as SHC025-58CHI-A; and the mutant genes were constructed by site-directed mutagenesis. The results of chimeric antibody sequencing are shown in Table 5. [Table 5]
[0026] Example 5 Construction and production of humanized antibodies According to the activity analysis, affinity KD value, etc. of the chimeric antibodies, SHC025-34CHI, SHC025-58CHI-A, and SHC025-26CHI-T were selected to carry out antibody humanization. The humanization of the antibody was first performed by comparing the SHC025-34CHI, SHC025-58CHI-A, and SHC025-26CHI-T antibodies with mouse antibody sequences in the Immunogen Gene Database (IMGT) to confirm the mouse origin of the variable regions of the antibodies, and comparing the homology. The FR regions of the heavy chain variable region sequences of the SHC025-34CHI, SHC025-58CHI-A, and SHC025-26CHI-T antibodies were found to be most similar to the mouse antibody-derived genes IGHV1-8*01, IGHV3-21*04, and IGHV1-2*02, respectively. The antibody light chain variable region FR sequences were found to be most similar to the mouse antibodies IGKV3-11*01, IGKV1-5*01, and IGKV4-1*01. Using the SHC025-34CHI / SHC025-58CHI-A antibody framework region sequence FR1-FR3 as a template, a fully human framework with a similar 3D structure but low immunogenicity was searched for in the human framework region library instead of the FR1-FR3 sequence of SHC025-34CHI / SHC025-58CHI-A. 3D construction was performed for the full-length heavy chain / light chain sequences, and a structural comparison analysis with the original antibody heavy chain / light chain sequences was performed. After comprehensively considering the antigenicity and 3D structural similarity, six humanized heavy chain variable regions (see SEQ ID NOs: 48, 49, 50, 51, 52, 53) of SHC025-34CHI, four humanized light chain variable regions (see SEQ ID NOs: 54, 55, 56, 57), and six humanized light chain variable regions (see SEQ ID NOs: 59, 60, 61, 62, 63) of SHC025-58CHI-A were finally selected. SHC025-26CHI-T heavy and light chain variable region sequences were used to perform structural alignment analysis in the Protein Data Bank, and the most similar FR1-FR3 sequences were selected to replace the mouse sequences, and amino acid sites that play an important role in the stability of the antibody structure in structural simulations were back-mutated to mouse-derived amino acid residues.Finally, four humanized heavy chain variable regions (see SEQ ID NOs: 69, 70, 71, 72) and two humanized light chain variable regions (see SEQ ID NOs: 73, 74) of SHC025-26CHI-T were obtained. The amino acid sequences of the humanized antibody light and heavy chain variable regions designed above were reverse transcribed into the corresponding nucleotide sequences to generate oligonucleotide fragments containing complementary sequences between adjacent fragments, and the oligonucleotide fragments were annealed and ligated by overlap PCR. The complete light and heavy chain variable region nucleotide fragments were then amplified using specific primers (containing homologous arm sequences at the 5' end for homologous recombination with eukaryotic expression vectors). The purified light chain variable region nucleotide fragments and the linearized eukaryotic expression plasmid containing the IgG4 light chain constant region were co-transformed into E. coli DH5α responsive cells, and the purified heavy chain variable region nucleotide fragments containing the S228P / L235E mutant IgG4 heavy chain constant region were co-transformed into E. coli DH5α responsive cells. The responsive cells transformed with the respective conversion plasmids were uniformly spread on the surface of the corresponding antibiotic agar plate, and cultured overnight in a constant temperature incubator at 37°C, after which some single colonies were selected for DNA sequencing. The positive clones with the correct sequence were inoculated into 2xYT liquid medium containing the corresponding antibiotics and cultured at 37°C with shaking for more than 12 hours. The cells were then harvested and the plasmids were extracted to obtain the humanized antibody light chain and heavy chain expression plasmids. The concentration and purity of the plasmids were detected by a nucleic acid quantitative analyzer. The plasmid was transfected into HEK293E cells, expressed and purified to obtain large amounts of antibody, which was subjected to purity detection, activity analysis and affinity detection. Humanized antibodies with good purity, activity and affinity were selected and designated Hu26T-31-PE, Hu34-39-PE and Hu58A-14-PE, and their sequences are shown in Table 6. The origins of the humanized antibodies are shown in Table 7. [Table 6] [Table 7]
[0027] Example 6 Measurement of binding activity to monkey CD47 (ELISA) The binding activity of the antibody was analyzed by protein-based Elisa. Cynomolgus CD47-His (0.1 μg / well, ACRO Biosystems, Cat. No. CD7-C52H1-50ug) was coated on a 96-well microplate. The anti-CD47 antibody provided by the present invention was added to the microplate in a 5-fold serial dilution starting from 2 μg / mL as the primary antibody, with a total of 8 concentrations, the concentrations being 2000 ng / mL, 400 ng / mL, 80 ng / mL, 16 ng / mL, 3.2 ng / mL, 0.64 ng / mL, 0.128 ng / mL, and 0 ng / mL, respectively, and incubated at 37°C for 1.5 h, and the positive control antibody was AB06.12-4P. Anti-Human IgG HRP (Jackson, 109-035-003, 1:10000) was used as the secondary antibody, and the color developer TMB (3,3',5,5'-tetramethylbenzidine) was added. After completion, the OD450 value was read using a microplate reader (thermo, Multiskan FC). EC50 was generated using GraphPad, and the results are shown in Figure 1. The experimental results showed that the humanized anti-CD47 antibodies Hu26T-31-PE, Hu34-39-PE, and Hu58A-14-PE provided by the present invention all have the ability to bind to cynomolgus monkey CD47, and their binding ability is equivalent to that of the positive control antibody AB06.12-4P. Example 7 Measurement of binding activity to human CD47 (ELISA) The binding activity was analyzed by ELISA. Human CD47-His protein (0.1ug / well, obtained in Examples 1 and 2) was coated onto a 96-well microplate and incubated at 37°C for 2h. After washing three times with 1xPBST, the plate was blocked with 5% Skil's milk at 4°C overnight. After washing three times with 1xPBST, the anti-CD47 antibody provided by the present invention was added to the microplate in a 5-fold serial dilution starting from 2 μg / mL as the primary antibody, with a total of eight concentrations, the concentrations being 2000ng / mL, 400ng / mL, 80ng / mL, 16ng / mL, 3.2ng / mL, 0.64ng / mL, 0.128ng / mL, and 0ng / mL, respectively, and incubated at 37°C for 1.5h. The positive control antibody was AB06.12-4P. After washing five times with 1xPBST, Anti-Human IgG HRP (Jackson, 109-035-003, 1:10000) was used as the secondary antibody, and incubated at 37°C for 40min. After washing five times with 1xPBST, the color-developing solution TMB was added, and after completion, the OD450 value was read by a microplate reader (thermo, Multiskan FC). EC50s were generated using GraphPad and the results are shown in Figure 2. The experimental results showed that the humanized anti-CD47 antibodies Hu26T-31-PE, Hu34-39-PE, and Hu58A-14-PE provided by the present invention all have the ability to bind to human CD47, and their binding ability is equivalent to that of the positive control antibody AB06.12-4P.
[0028] Example 8 Measurement of CD47 binding to the cell surface (ELISA) The binding activity of the antibodies was analyzed by cell-based Elisa. CHO-K1-E5 cells were cultured at 1x10 per well. 5The cells were plated and cultured overnight at 37°C and 5% CO2, and on the second day, they were fixed with 4% paraformaldehyde and then blocked with skil milk for 1h. The plate was gently washed with 1xPBS. The anti-CD47 antibody provided by the present invention was added to the microplate in a 5-fold serial dilution starting from 2μg / mL as the primary antibody, with a total of 8 concentrations, the concentrations being 2000ng / mL, 400ng / mL, 80ng / mL, 16ng / mL, 3.2ng / mL, 0.64ng / mL, 0.128ng / mL, and 0ng / mL, respectively, and incubated at 37°C for 1.5h, and the positive control antibody was AB06.12-4P. Anti-Human IgG HRP (Jackson, 109-035-003, 1:10000) was used as the secondary antibody, and TMB was added as a coloring agent. After completion, the OD450 value was read using a microplate reader (thermo, Multiskan FC). EC50 was generated using GraphPad, and the results are shown in Figure 3. The experimental results showed that the humanized anti-CD47 antibodies Hu26T-31-PE, Hu34-39-PE, and Hu58A-14-PE provided by the present invention all have the ability to bind to human CD47, and their binding ability is equivalent to that of the positive control antibody AB06.12-4P.
[0029] Example 9 Measurement of affinity to human CD47 protein The binding affinity of the humanized anti-CD47 antibodies obtained in Examples 1 and 2 to the antigen CD47(19-136)-hFC was measured using Fortebio Octet. First, the antigen CD47(19-136)-hFc was labeled by biotinylation, then subjected to PBS centrifugal ultrafiltration using a 10 kD ultrafiltration tube, desalted 3 to 4 times, and the actual concentration of the antigen CD47-hFc-Biotin after biotin labeling was measured using Nanodrop. CD47-hFc-Biotin was diluted with SD buffer (0.02% Tween20 + 0.1% BSA solution) to a concentration of 5ug / ml, and the humanized anti-CD47 antibody was diluted 4-fold with SD buffer to have concentrations of 10ug / ml, 2.5ug / ml, 0.625ug / ml, and 0ug / ml. The antigen was immobilized on an SA sensor, and affinity measurement was performed according to the fortebio Octet RED96 protocol. The specific parameters and experimental results are shown in Table 8. [Table 8] The experimental results showed that Hu26T-31-PE had higher binding affinity to human CD47 protein than the positive control antibody.
[0030] Example 10 Hemagglutination test 5mL of blood was collected, 40mL of PBS was added, and the blood was centrifuged lightly at 2000rpm for 5min, the supernatant was discarded, the blood was washed three times with PBS, the red blood cells were resuspended in PBS, and a 2% red blood cell suspension was prepared according to the hematocrit value of the red blood cells. The antibodies to be analyzed had an initial concentration of 1-20uM, and were diluted two-fold in a stepwise manner, resulting in a total of 24 concentration gradients. 50μL of antibodies of different concentrations were added to a round-bottom 96-well plate, and 50ul of the above 2% red blood cell suspension was added, mixed uniformly, and left at room temperature. After 2 hours, it was observed whether there was agglutination. Rabbit polyclonal antibody RBC antibody (Rockland, 109-4139) was used as a positive control for the occurrence of hemagglutination, and the results are shown in Figure 4. As shown in Figure 4, the concentrations of antibodies (rabbit polyclonal antibody RBC antibody, AB06.12-4P antibody and the test antibody of the present invention) added from left to right in a 96-well plate were diluted in a 2-fold gradient starting from 20uM, where RBC represented the positive control group (using rabbit polyclonal antibody RBC antibody, which significantly induces red blood cell agglutination), and PBS represented the blank control group. In the wells, the red blood cells appeared as small round dots, with neat edges indicating no cell agglutination, slightly irregular edges indicating a small amount of red blood cell agglutination, and flaky, covering the bottom of the wells indicated most of the red blood cells were agglutinated. Experiments show that the anti-CD47 antibody Hu5F9-G4 disclosed in patent application WO2011 / 143624 can cause significant agglutination of most red blood cells in the same concentration range, which is a common undesirable phenomenon of anti-CD47 antibodies.However, under the same conditions, the experimental results show that the Hu26T-31-PE, Hu34-39-PE, and Hu58A-14-PE of the present invention all do not cause red blood cell agglutination, and the antibodies of the present invention are obviously superior to the antibody Hu5F9-G4 in this respect.
[0031] Example 11: Experiment to measure CD47 inhibitory activity by FACS FACS was used to detect the ability of the anti-CD47 antibodies provided by the present invention to inhibit the binding of SIRPa to cell surface CD47. The CHO-K1-E5 positive cell line was used as the source of CD47, and the binding ability of CD47 to SIRPa was observed in the presence of serially diluted anti-CD47 antibodies. PE Streptavidin (Biolegend, 405203, 1:200) was used as the secondary antibody to monitor the change in SIRPa-Biotin. AB06.12-4P is a positive control that inhibits SIRPa binding to cell surface CD47. The average value was read at a wavelength of 585 nm using a flow cytometer (BD, FACSJazz), and IC50 was generated using GraphPad, and the results are shown in Figure 5. The experimental results showed that the inhibitory activity was in the order of Hu26T-31-PE≧Hu34-39-PE≧AB06.12-P>Hu58A-14-PE.
[0032] Example 12 Antitumor test in human gastric cancer NUGC-4 xenograft tumor model 1. Experimental materials (1) Experimental cells and animals NUGC-4 human gastric cancer cells were purchased from the American Type Culture Collection (ATCC); NOD-Scid mice, female, 5-8 weeks old, weighing 18-20 g, were purchased from Shanghai Lingchang Biological Technology Co., Ltd. (2) Test and control items The control product isotype IgG4 (catalog number AB170091) was purchased from Zhongmei Guanke Biotechnology Co. Ltd. and used as a negative control product. Prior to testing, the humanized anti-CD47 antibody of the present invention was prepared in PBS at two concentrations, 0.6 mg / mL and 0.3 mg / mL, and isotype IgG4 and AB 06.12-4P were prepared at 0.6 mg / mL. (3) Experimental Method NUGC-4 human gastric cancer cells were cultured in RMPI1640 medium containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL rocomycin in an incubator at 37 °C and 5% CO2. They were passaged once a week by digestion with 2 mL of 1 × EDTA solution. When the cells reached 80% to 90% saturation, they were harvested, counted, and seeded. 5 × 10 6 PBS containing 5 × 10 cells was mixed with 100 μL of Matrigel (final volume 200 μL) and seeded on the right hindquarters of mice. The number of cells seeded was 5 × 10 6 cells / animal. Tumor volume is 150-200 mm 3 When the mice grew to 100 mm, they were divided into groups and intraperitoneally injected three times a week. The diameter of the tumor was measured three times a week using a Vernier caliper, and the tumor volume was calculated using the formula V=0.5a×b. 2 where a and b indicate the long and short diameters of the tumor, respectively. The antitumor effect of the antibody was evaluated by the relative tumor growth rate T / C (%). The calculation formula for the relative tumor growth rate T / C (%) is T / C%=TRTV / CRTV×100% (TRTV: treatment group RTV, CRTV: negative control group RTV). RTV=V21 / V0, where V0 is the tumor volume measured at the time of administration in the group (i.e., d0), and V21 is the tumor volume measured on the 21st day of administration. The tumor volumes on the final day (day 21) of the administration group and the vehicle group were analyzed by T-test and run in GraphPad Prism. The results are shown in Table 9. [Table 9] The experimental results showed that the antibody provided by the present invention had a significant antitumor effect when human gastric cancer NUGC-4 cells were inoculated into a NOD-SCID mouse transplanted tumor model. Hu26T-31-PE and Hu34-39-PE at a dose of 3 mg / kg had a similar tumor inhibitory effect to the control antibody AB06.12-4P at 6 mg / kg, but the tumor inhibitory effect of Hu26T-31-PE and Hu34-39-PE at a dose of 6 mg / kg was superior to that of the control antibody AB06.12-4P at 6 mg / kg. One week after the administration was stopped, tumor recurrence occurred in the 6 mg / kg control antibody group. However, no recurrence occurred in the Hu26T-31-PE and Hu34-39-PE groups (FIGS. 6 and 7). The anti-CD47 antibody provided by the present invention unexpectedly showed a more significant inhibitory effect on tumor growth.
[0033] The above examples demonstrate that the anti-CD47 antibody provided in the present invention has significant anti-tumor effect and can significantly inhibit tumor growth, suggesting that the antibody is applicable for the preparation of anti-tumor drugs and has predictable market prospects.
[0034] Although the present invention has been described in detail above, it should be understood that those skilled in the art can make various modifications and changes to the present invention without departing from the spirit and scope of the present invention. The scope of the present invention should not be limited to the above detailed description, but should belong to the claims.
Claims
1. 1. An anti-CD47 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, (1) the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1, HCDR2 and HCDR3 are represented by SEQ ID NOs: 4, 5 and 6; (2) An anti-CD47 antibody or an antigen-binding fragment thereof, wherein the light chain variable region comprises LCDR1, LCDR2 and LCDR3, and the LCDR1, LCDR2 and LCDR3 are represented by SEQ ID NOs: 15, 16 and 17.
2. The anti-CD47 antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a mouse monoclonal antibody, a human / mouse chimeric antibody or a humanized antibody.
3. The CD47 antibody or antigen-binding fragment thereof of claim 1, wherein the antibody further comprises a heavy chain constant region of mouse IgG1, IgG2 or a variant thereof, and a light chain constant region of mouse-derived k chain or a variant thereof.
4. 2. The anti-CD47 antibody or antigen-binding fragment thereof of claim 1, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 22 and the amino acid sequence of the light chain variable region is SEQ ID NO:
25.
5. 2. The anti-CD47 antibody or antigen-binding fragment thereof of claim 1, wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 30 and the amino acid sequence of the light chain variable region is SEQ ID NO:
33.
6. An isolated nucleic acid encoding the anti-CD47 antibody or antigen-binding fragment thereof of any one of claims 1 to 5.
7. (1) The nucleotide sequence encoding the heavy chain variable region amino acid sequence is represented by SEQ ID NO: 36, (2) The nucleic acid of claim 6, wherein the nucleotide sequence encoding the light chain variable region amino acid sequence is represented by SEQ ID NO:
39.
8. A pharmaceutical composition comprising the anti-CD47 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 and a pharma- ceutical acceptable carrier.
9. The pharmaceutical composition of claim 8, used to treat cancer by inhibiting CD47 activity.
10. The pharmaceutical composition described in claim 9, wherein the cancer is leukemia, lymphatic cancer, breast cancer, lung cancer, gastric cancer, colon cancer, esophageal cancer, ovarian cancer, cervical cancer, renal cancer, bladder cancer, pancreatic cancer, glioma and / or melanoma.
Citation Information
Patent Citations
Platelet-non-reducing and erythrocyte-non-reducing CD47 antibodies and methods of using the same
JP2016507555A
Anti-CD147 Antibodies, Methods, and Uses
JP2018502060A
Anti-CD47 antibodies and methods of use
WO2017053423A1
Novel CD47 monoclonal antibodies and uses thereof
WO2018075857A1
